




FIG. 1




FIG. 1 (cont.)




FIG. 2




FIG. 3

Favored Baseline Variables*	Responders (n=29)		Early Responders (n=21)	
	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
Duration of ITP (increase by 1 year)	0.97 (0.93, 1.01)	0.10	0.95 (0.90, 1.00)	0.07
Baseline platelet count (increase by 1×10 ⁹ /L)	1.08 (1.01, 1.15)	0.02	1.11 (1.03, 1.19)	0.005
Number of prior therapies (increase by 1)	0.94 (0.87, 1.01)	0.08	0.93 (0.85, 1.02)	0.11
No prior ITP therapy				
Splenectomy	1.93 (0.67, 5.55)	0.22	2.61 (0.76, 8.91)	0.13
TPO-RA	4.24 (1.36, 13.20)	0.01	4.77 (1.52, 14.96)	0.007
Rituximab	2.18 (0.83, 5.74)	0.11	3.45 (1.15, 10.38)	0.03
No concomitant ITP medication				
TPO-RA	1.31 (0.47, 3.70)	0.61	1.65 (0.52, 5.27)	0.40
CS	0.82 (0.28, 2.42)	0.72	0.79 (0.25, 2.49)	0.69

FIG. 4A




FIG. 4B

ITP-PAQ Domains	MID Reference	Median Change	
		From Baseline	HRQOL to Wk 25 HRQOL
Women's reproductive health*	8-12		21
Overall HRQOL	8-12		13
Fatigue/sleep	10-15		13
Activity	10-15		13
Psychological health	8-12		7.5
Social activity	8-12		6
Symptoms	8-12		6
Bother-physical health	8-12		4
Fear	NE		3
Work	NE		0

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10



Number of Participants

133	114	100	91	90	83	63	55	54	54	54	53	18
69	55	44	38	32	30	14	6	6	6	6	6	3

FIG. 11




FIG. 12




FIG. 13




FIG. 14